Pyxis Oncology, Inc. Financing Cash Flow
Pyxis Oncology, Inc. (PYXS) reported Financing Cash Flow of $9.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Pyxis Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $9.99M.
- Pyxis Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$25.00K.
- Pyxis Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $669.00K, a 1238.00% increase year-over-year.
- Pyxis Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$8.00K, a 100.48% decline year-over-year.
- Pyxis Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $594.00K, a 99.00% decline from fiscal 2024.
- Pyxis Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $59.33M, a 900.61% increase from fiscal 2023.
- Pyxis Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $5.93M, a 3139.89% increase from fiscal 2022.
- Pyxis Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $183.00K, a 99.94% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $9.97M 10-Q · filed 2026-08-13 | $10.64M derived: sum of 3 quarters · filed 2026-08-13 | $10.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$25.00K 10-Q · filed 2026-05-14 | $644.00K derived: sum of 2 quarters · filed 2026-05-14 | $636.00K derived: sum of 3 quarters · filed 2026-05-14 | $569.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $669.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $661.00K derived: sum of 2 quarters · filed 2026-03-23 | $594.00K derived: sum of 3 quarters · filed 2026-08-13 | $594.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | -$8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$75.00K derived: sum of 2 quarters · filed 2026-08-13 | -$75.00K 10-Q · filed 2025-11-03 | -$25.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$67.00K 10-Q · filed 2026-08-13 | -$17.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $50.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.71M derived: sum of 3 quarters · filed 2026-05-14 | $1.81M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.71M derived: sum of 2 quarters · filed 2026-03-23 | $1.81M derived: sum of 3 quarters · filed 2026-03-23 | $59.33M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $1.76M derived: sum of 2 quarters · filed 2025-11-03 | $59.28M 10-Q · filed 2025-11-03 | $59.25M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $57.62M 10-Q · filed 2025-08-14 | $57.60M derived: sum of 3 quarters · filed 2025-08-14 | $57.42M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $57.51M 10-Q · filed 2025-05-15 | $57.49M derived: sum of 2 quarters · filed 2025-05-15 | $57.31M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$196.00K derived: sum of 2 quarters · filed 2025-03-18 | $5.93M 10-K · filed 2025-03-18 | |
| 2023-09-30 | -$171.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.95M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $6.13M 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $6.00K derived: sum of 2 quarters · filed 2024-03-21 | $7.00K derived: sum of 3 quarters · filed 2024-03-21 | $183.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $7.00K derived: sum of 2 quarters · filed 2023-11-07 | $183.00K 10-Q · filed 2023-11-07 | $155.08M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $177.00K 10-Q · filed 2023-08-11 | $155.08M derived: sum of 3 quarters · filed 2023-08-11 | $153.37M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $176.00K 10-Q · filed 2023-05-11 | $155.08M derived: sum of 2 quarters · filed 2023-05-11 | $153.37M derived: sum of 3 quarters · filed 2023-05-11 | $152.69M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $154.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $153.19M derived: sum of 2 quarters · filed 2023-03-22 | $152.51M derived: sum of 3 quarters · filed 2023-03-22 | $304.04M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$2.39M derived: sum of 2 quarters · filed 2022-11-01 | $149.14M 10-Q · filed 2022-11-01 | $149.15M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | -$682.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $150.85M 10-Q · filed 2022-08-15 | $150.85M derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $151.53M 10-Q · filed 2022-05-13 | $151.53M derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $35.00K 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $34.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |